Stocks · News reference
Utah Medical Products, Inc. reported its financial results for the third quarter and first nine months of 2026, noting a decline in revenue compared to the prior year due to the loss of two major customers.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The South Korean Ministry of Food and Drug Safety has designated Utah Medical Products' Dialy-Nate Set and Dialy-Nate Catheter as crucial medical supplies for neonatal and pediatric dialysis.
Utah Medical Products, Inc. announced that its Board of Directors approved a quarterly cash dividend of $0.315 per share, representing a 1.6% increase over the previous regular quarterly dividend.
Filed: 2026-11-03 AccNo: 0001096906-26-001664 Size: 146 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Utah Medical Products, Inc. announced the final results of its tender offer, which expired on October 27, 2026, resulting in the purchase of 327,740 shares of its common stock.
Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.